Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
32 hedge funds and large institutions have $583K invested in Viracta Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 11 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less funds holding
Funds holding: 38 → 32 (-6)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
55% less capital invested
Capital invested by funds: $1.29M → $583K (-$709K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$25.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$20.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.3K |
| 4 |
Jane Street
New York
|
+$10.9K |
| 5 |
Renaissance Technologies
New York
|
+$8.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$160K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$131K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$116K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$76.9K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$15.8K |
VIRX Hedge Fund Activity: Q4 2024 in Review
32 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2024, worth a combined $583K — down 55% from $1.29M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VIRX and 6 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $25.2K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $160K sold.
- 32 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2024, down from 38 in Q3 2024.
- Funds reported $583K of Viracta Therapeutics, Inc. Common Stock stock for Q4 2024, down 55% quarter-over-quarter.
- 6 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2024 and 11 closed out, a net change of -5 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2024 was Virtu Financial, an estimated $25.2K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2024 was Samsara BioCapital, an estimated $160K sold.
Based on aggregated 13F filings for Q4 2024.